(Adds Brazil, Mexico and Argentina's deals with Russia and AstraZeneca) Sept 11 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing. Over 30 candidates are being studied in humans. The following is a list of supply deals for potential vaccines that give some countries a guarantee of a limited number of doses: COUNTRY/REGIO COMPANY DEAL TERM NO OF DOSES DELIVERY DATE STORY LINK N U.S. Moderna Inc $1.53 bln 100 mln, with option of Not specified additional 400 mln doses U.S. Pfizer Inc and $1.95 bln 100 mln @ 2 per person. Option By October BioNTech SE for 500 mln more U.S. AstraZeneca Plc $1.2 bln 300 mln likely @ 2 per person By October U.S. Novavax Inc $1.6 bln 100 mln By January 2021 U.S. Johnson & Johnson Over $1 bln 100 mln; U.S. may buy 200 mln Not Specified more doses under a subsequent agreement U.S. Sanofi SA and $2.1 bln 100 mln; option for 500 mln Not Specified GlaxoSmithKline Plc more EU AstraZeneca Not specified At least 300 mln, option for Not specified 100 mln additional doses EU Johnson & Johnson In talks 200 mln, option for additional Not Specified 200 mln doses EU Sanofi SA and In talks 300 mln Not Specified GlaxoSmithKline EU Moderna In talks 80 mln doses Not Specified EU CureVac In talks 225 mln doses, option to supply Not Specified 180 mln additional doses EU BioNTech/ Pfizer Concluded Initial 200 mln doses with Not Specified exploratory talks option to buy 100 mln more Italy, AstraZeneca 750 mln euros 300 mln with option to buy 100 Not Applicable Germany, the ($843 million) mln more Netherlands and France UK Johnson & Johnson Non-profit basis 30 mln doses on not-for-profit Not specified for emergency use; basis, option for additional option to purchase purchase of up to 22 mln doses additional doses UK Novavax Not specified 60 mln doses, and plan for a By early 2021; phase 3 late-stage trial in UK with trial in Q3 2020 govt support UK Valneva "Multi-million 60 mln with an option to Not Applicable pound" investment purchase 40 million mln UK Sanofi , Financial terms Up to 60 mln Not Applicable GlaxoSmithKline undisclosed UK Pfizer and BioNTech Financial terms 30 mln Not Applicable undisclosed UK AstraZeneca 65.5 mln pounds in Up to 30 mln doses (part of a September total commitment to deliver 100 mln total) Canada Pfizer and BioNTech Financial details Not specified Over the course of 2021 not disclosed Canada Moderna Not specified Not specified Not Specified Canada Novavax Not specified Up to 76 million doses 2Q of 2021 Japan Moderna In talks 40 million or more doses, to be First half of 2021 distributed by Takeda Japan Pfizer and BioNTech Financial details 120 mln First half of 2021 were not disclosed Japan Johnson & Johnson In talks Not Applicable Not Applicable Japan AstraZeneca Co-production with 120 mln First 30 mln expected by JCR Pharma March 2021 , Daiichi Sankyo Biotech and KM Biologics Japan Novavax Co-production with 250 mln Production is yearly Takeda estimate Europe, Latin Arcturus Therapeutics In talks Not Applicable Not Applicable America and Holdings Inc Southeast Asia Israel Arcturus Therapeutics $275 million Initial one mln doses, with the Not Applicable Holdings Inc option to buy additional doses Israel Moderna Financial terms Not Applicable Not Applicable were not disclosed Indonesia Sinovac Biotech Ltd Financial terms At least 40 mln doses By March 2021 were not disclosed China AstraZeneca Produced by At least 200 mln doses of By end 2021 Shenzhen Kangtai production capacity Biological Products Brazil Gamaleya Research Institute Not disclosed Brazil's Bahia state to get 50 To start in November and Russian Direct mln doses and will conduct Investment Fund Phase III clinical trials of Sputnik V Brazil AstraZeneca $356 mln to buy 100 mln doses December/January and produce the vaccine Mexico Gamaleya, Russian Direct Financial terms 32 mln doses November Investment Fund not specified Mexico, AstraZeneca To produce the 150 mln doses, could go up to First half of 2021 Argentina vaccine for most 250 mln of Latin America (Reporting By Mrinalika Roy, Manojna Madippatla and Trisha Roy in Bengaluru, Rocky Swift in Tokyo; Editing by Sriraj Kalluvila, Shounak Dasgupta, Aditya Soni, Vinay Dwivedi)
Our Standards: The Thomson Reuters Trust Principles.